<p>法国马赛 --（商业资讯）-- 监管新闻：</p>
<p>根据法国《商业法典》第 L. 233-8 II 条和法国证券市场监管机构（“AMF”）一般规定第 223-16 条，Innate Pharma SA（巴黎泛欧交易所代码：IPH；纳斯达克代码：IPHA）（“Innate” 或 “公司”）发布截至 2025 年 12 月 18 日的总流通股数及其投票权：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>总流通股数：</td>
<td></td>
<td></td>
<td></td>
<td>92,197,823 普通股</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6,324 2016 年优先股</td>
</tr>
<tr>
<td>7,581 2017 年优先股</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>理论投票权总数（1）：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>可行使投票权总数（2）：</td>
<td></td>
<td></td>
<td></td>
<td>92,962,943</td>
</tr>
<tr>
<td>92,944,368</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>(1) 理论投票权总数（或称 “总” 投票权）用于计算股权阈值的跨越。根据 AMF 一般规定第 223-11 条，该数字是基于所有附有投票权的股份计算的，包括投票权被暂停的股份。理论投票权总数包括附有 AGAP 2016 的投票权，即 AGAP 2016-1 的 130 个投票权和 AGAP 2016-2 的 111 个投票权。AGAP 2017 不附有投票权。</em></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><em>(2) 可行使投票权总数（或称 “净” 投票权）是在不考虑公司持有的库存股和暂停投票权的股份的情况下计算的。此信息的发布旨在确保市场得到充分信息，符合 AMF 于 2007 年 7 月 17 日提出的建议。</em></td>
</tr>
</tbody>
</table>
<p><strong>关于 Innate Pharma</strong></p>
<p>Innate Pharma S.A.是一家全球性的临床阶段生物技术公司，专注于为癌症患者开发免疫疗法。凭借其在抗体工程和创新靶点识别方面的专业知识，Innate Pharma 正在开发创新和差异化的下一代抗体治疗药物。</p>
<p>Innate Pharma 正在推进一系列差异化的潜在首创和/或最佳资产，重点关注高未满足医疗需求的领域，包括 IPH4502，这是一种在实体肿瘤中开发的差异化 Nectin-4 ADC，lacutamab，这是一种在皮肤 T 细胞淋巴瘤和外周 T 细胞淋巴瘤中开发的抗 KIR3DL2 抗体，以及 monalizumab，这是一种与阿斯利康合作开发的抗 NKG2A 抗体，针对非小细胞肺癌。</p>
<p>Innate Pharma 已与领先的生物制药公司（包括赛诺菲和阿斯利康）以及著名的学术和研究机构建立了合作关系，以推动免疫肿瘤学的创新。</p>
<p>Innate Pharma 总部位于法国马赛，在美国马里兰州洛克维尔设有办事处，已在巴黎泛欧交易所和美国纳斯达克上市。</p>
<p>了解更多关于 Innate Pharma 的信息，请访问 www.innate-pharma.com，并在 LinkedIn 和 X 上关注我们。</p>
<p><strong>关于 Innate Pharma 股份的信息</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ISIN 代码</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>股票代码</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LEI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FR0010331421</td>
</tr>
<tr>
<td>泛欧交易所：IPH 纳斯达克：IPHA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9695002Y8420ZB8HJE29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p><strong>关于前瞻性信息和风险因素的免责声明</strong></p>
<p>本新闻稿包含某些前瞻性声明，包括适用证券法下的声明，包括 1995 年私人证券诉讼改革法案的定义。使用某些词汇，包括 “预期”、“相信”、“可以”、“可能”、“估计”、“期望”、“可能”、“潜在”、“打算”、“应该”、“将” 或这些词的否定形式及类似表达，旨在识别前瞻性声明。尽管公司相信其预期基于合理假设，但这些前瞻性声明面临众多风险和不确定性，可能导致实际结果与预期结果存在重大差异。这些风险和不确定性包括，除了其他事项外，研究和开发固有的不确定性，包括与其正在进行和计划中的临床试验和临床前研究的安全性、进展和结果相关的风险，监管机构对其产品候选者的审查和批准，公司对第三方制造其产品候选者的依赖，公司商业化努力以及公司持续筹集资金以支持其开发的能力。有关可能导致公司实际结果、财务状况、业绩或成就与前瞻性声明中所包含的内容不同的风险和不确定性的进一步讨论，请参阅提交给法国金融市场管理局（“AMF”）的《通用注册文件》中 “风险因素”（“Facteurs de Risque”）部分，该文件可在 AMF 网站 http://www.amf-france.org 或 Innate Pharma 网站上找到，以及向美国证券交易委员会（“SEC”）提交的公共文件和报告，包括截至 2024 年 12 月 31 日的年度报告 20-F 及随后向 AMF 或 SEC 提交的文件和报告，或公司以其他方式公开的信息。提及公司网站和 AMF 网站仅供参考，所包含的内容或可以通过它们访问的内容不构成本新闻稿的一部分，也不被纳入引用。</p>
<p>鉴于这些前瞻性声明中存在重大不确定性，您不应将这些声明视为公司或任何其他人对公司将在任何特定时间框架内或根本上实现其目标和计划的陈述或保证。公司没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律要求的情况除外。</p>
<p>本新闻稿及其中包含的信息不构成在任何国家出售或购买或认购 Innate Pharma 股份的要约或邀请。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjE3MjcwMzFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjE3MjcwMzFyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251221727031/en/</p>
<p><strong>如需更多信息，请联系：</strong></p>
<p><strong>Innate Pharma</strong></p>
<p>Stéphanie Cornen</p>
<p>stephanie.cornen@innate-pharma.fr</p>
<p><strong>投资者关系</strong></p>
<p>investors@innate-pharma.fr</p>
<p><strong>媒体</strong></p>
<p>communication@innate-pharma.com</p>
<p>来源：Innate Pharma SA</p>

IPHA

<p>Innate Pharma SA 宣布截至 2025 年 12 月 18 日的总股份和投票权数量。该公司拥有 92,197,823 股普通股、6,324 股 2016 年优先股和 7,581 股 2017 年优先股。总理论投票权为 92,962,943，而可行使的投票权为 92,944,368。Innate Pharma 是一家临床阶段的生物技术公司，专注于为癌症患者开发免疫疗法</p>

<p>MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:</p>
<div class="lb-trans"><p>法国马赛 --（商业资讯）-- 监管新闻：</p>
</div><p>Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( <em>Autorité des Marchés Financiers</em>, or “ <strong>AMF</strong>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ <strong>Innate</strong>” or the “ <strong>Company</strong>”) releases its total number of shares outstanding as well as its voting rights as of December 18, 2025:</p>
<div class="lb-trans"><p>根据法国《商业法典》第 L. 233-8 II 条和法国证券市场监管机构（“AMF”）一般规定第 223-16 条，Innate Pharma SA（巴黎泛欧交易所代码：IPH；纳斯达克代码：IPHA）（“Innate” 或 “公司”）发布截至 2025 年 12 月 18 日的总流通股数及其投票权：</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of shares outstanding:</td>
<td></td>
<td></td>
<td></td>
<td>92,197,823 ordinary shares</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6,324 Preferred Shares 2016<br/>7,581 Preferred Shares 2017</td>
</tr>
<tr>
<td>Total number of theoretical voting rights (1):<br/>Total number of exercisable voting rights (2):</td>
<td></td>
<td></td>
<td></td>
<td>92,962,943<br/>92,944,368</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>总流通股数：</td>
<td></td>
<td></td>
<td></td>
<td>92,197,823 普通股</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6,324 2016 年优先股</td>
</tr>
<tr>
<td>7,581 2017 年优先股</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>理论投票权总数（1）：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>可行使投票权总数（2）：</td>
<td></td>
<td></td>
<td></td>
<td>92,962,943</td>
</tr>
<tr>
<td>92,944,368</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.</em></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><em>(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.</em></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>(1) 理论投票权总数（或称 “总” 投票权）用于计算股权阈值的跨越。根据 AMF 一般规定第 223-11 条，该数字是基于所有附有投票权的股份计算的，包括投票权被暂停的股份。理论投票权总数包括附有 AGAP 2016 的投票权，即 AGAP 2016-1 的 130 个投票权和 AGAP 2016-2 的 111 个投票权。AGAP 2017 不附有投票权。</em></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><em>(2) 可行使投票权总数（或称 “净” 投票权）是在不考虑公司持有的库存股和暂停投票权的股份的情况下计算的。此信息的发布旨在确保市场得到充分信息，符合 AMF 于 2007 年 7 月 17 日提出的建议。</em></td>
</tr>
</tbody>
</table>
</div><p><strong>About Innate Pharma</strong></p>
<div class="lb-trans"><p><strong>关于 Innate Pharma</strong></p>
</div><p>Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.</p>
<div class="lb-trans"><p>Innate Pharma S.A.是一家全球性的临床阶段生物技术公司，专注于为癌症患者开发免疫疗法。凭借其在抗体工程和创新靶点识别方面的专业知识，Innate Pharma 正在开发创新和差异化的下一代抗体治疗药物。</p>
</div><p>Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.</p>
<div class="lb-trans"><p>Innate Pharma 正在推进一系列差异化的潜在首创和/或最佳资产，重点关注高未满足医疗需求的领域，包括 IPH4502，这是一种在实体肿瘤中开发的差异化 Nectin-4 ADC，lacutamab，这是一种在皮肤 T 细胞淋巴瘤和外周 T 细胞淋巴瘤中开发的抗 KIR3DL2 抗体，以及 monalizumab，这是一种与阿斯利康合作开发的抗 NKG2A 抗体，针对非小细胞肺癌。</p>
</div><p>Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.</p>
<div class="lb-trans"><p>Innate Pharma 已与领先的生物制药公司（包括赛诺菲和阿斯利康）以及著名的学术和研究机构建立了合作关系，以推动免疫肿瘤学的创新。</p>
</div><p>Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.</p>
<div class="lb-trans"><p>Innate Pharma 总部位于法国马赛，在美国马里兰州洛克维尔设有办事处，已在巴黎泛欧交易所和美国纳斯达克上市。</p>
</div><p>Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.</p>
<div class="lb-trans"><p>了解更多关于 Innate Pharma 的信息，请访问 www.innate-pharma.com，并在 LinkedIn 和 X 上关注我们。</p>
</div><p><strong>Information about Innate Pharma shares</strong></p>
<div class="lb-trans"><p><strong>关于 Innate Pharma 股份的信息</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ISIN code</strong><br/><strong>Ticker code</strong><br/><strong>LEI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FR0010331421<br/>Euronext: IPH Nasdaq: IPHA<br/>9695002Y8420ZB8HJE29</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ISIN 代码</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>股票代码</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LEI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FR0010331421</td>
</tr>
<tr>
<td>泛欧交易所：IPH 纳斯达克：IPHA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9695002Y8420ZB8HJE29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p><strong>Disclaimer on forward-looking information and risk factors</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性信息和风险因素的免责声明</strong></p>
</div><p>This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “intend,” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque&#34;) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.</p>
<div class="lb-trans"><p>本新闻稿包含某些前瞻性声明，包括适用证券法下的声明，包括 1995 年私人证券诉讼改革法案的定义。使用某些词汇，包括 “预期”、“相信”、“可以”、“可能”、“估计”、“期望”、“可能”、“潜在”、“打算”、“应该”、“将” 或这些词的否定形式及类似表达，旨在识别前瞻性声明。尽管公司相信其预期基于合理假设，但这些前瞻性声明面临众多风险和不确定性，可能导致实际结果与预期结果存在重大差异。这些风险和不确定性包括，除了其他事项外，研究和开发固有的不确定性，包括与其正在进行和计划中的临床试验和临床前研究的安全性、进展和结果相关的风险，监管机构对其产品候选者的审查和批准，公司对第三方制造其产品候选者的依赖，公司商业化努力以及公司持续筹集资金以支持其开发的能力。有关可能导致公司实际结果、财务状况、业绩或成就与前瞻性声明中所包含的内容不同的风险和不确定性的进一步讨论，请参阅提交给法国金融市场管理局（“AMF”）的《通用注册文件》中 “风险因素”（“Facteurs de Risque”）部分，该文件可在 AMF 网站 http://www.amf-france.org 或 Innate Pharma 网站上找到，以及向美国证券交易委员会（“SEC”）提交的公共文件和报告，包括截至 2024 年 12 月 31 日的年度报告 20-F 及随后向 AMF 或 SEC 提交的文件和报告，或公司以其他方式公开的信息。提及公司网站和 AMF 网站仅供参考，所包含的内容或可以通过它们访问的内容不构成本新闻稿的一部分，也不被纳入引用。</p>
</div><p>In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p>
<div class="lb-trans"><p>鉴于这些前瞻性声明中存在重大不确定性，您不应将这些声明视为公司或任何其他人对公司将在任何特定时间框架内或根本上实现其目标和计划的陈述或保证。公司没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，法律要求的情况除外。</p>
</div><p>This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.</p>
<div class="lb-trans"><p>本新闻稿及其中包含的信息不构成在任何国家出售或购买或认购 Innate Pharma 股份的要约或邀请。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjE3MjcwMzFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251221727031r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251221727031/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251221727031/en/</p>
</div><p><strong>For additional information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，请联系：</strong></p>
</div><p><strong>Innate Pharma</strong></p>
<div class="lb-trans"><p><strong>Innate Pharma</strong></p>
</div><p>Stéphanie Cornen</p>
<div class="lb-trans"><p>Stéphanie Cornen</p>
</div><p>stephanie.cornen@innate-pharma.fr</p>
<div class="lb-trans"><p>stephanie.cornen@innate-pharma.fr</p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投资者关系</strong></p>
</div><p>investors@innate-pharma.fr</p>
<div class="lb-trans"><p>investors@innate-pharma.fr</p>
</div><p><strong>Medias</strong></p>
<div class="lb-trans"><p><strong>媒体</strong></p>
</div><p>communication@innate-pharma.com</p>
<div class="lb-trans"><p>communication@innate-pharma.com</p>
</div><p>Source: Innate Pharma SA</p>
<div class="lb-trans"><p>来源：Innate Pharma SA</p>
</div>

截至2025年12月18日，Innate Pharma 的股份数量和投票权情况 | IPHA 股票新闻